Experienced in Synovial Sarcoma

Ofer Merimsky

Department Of Otolaryngology Head And Neck Surgery, 
Tel Aviv, TA, IL 
Experienced in Synovial Sarcoma
Department Of Otolaryngology Head And Neck Surgery, 
Tel Aviv, TA, IL 
OverviewLocationsClinical Research

Overview

Ofer Merimsky practices in Tel Aviv, Israel. Merimsky is rated as an Experienced expert by MediFind in the treatment of Synovial Sarcoma. Their top areas of expertise are Adult Soft Tissue Sarcoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Retroperitoneal Inflammation.

Their clinical research consists of co-authoring 55 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Synovial Sarcoma.

Locations

Department Of Otolaryngology Head And Neck Surgery, Tel Aviv, TA, Israel
Other Locations
Ramat Aviv, TA 69978, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

55 Total Publications

How Far Can We Push the Limit in Palliative Surgery? A Case Report of Massive Chondroblastic Osteosarcoma of the Maxilla.
How Far Can We Push the Limit in Palliative Surgery? A Case Report of Massive Chondroblastic Osteosarcoma of the Maxilla.
Journal: Ear, nose, & throat journal
Published: July 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Merimsky's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile